- GSK Pharma India’s first-quarter net income was 2.05 billion rupees, marking a 13% increase year-over-year, but fell short of the estimated 2.1 billion rupees.
- Revenue for the quarter was 8.05 billion rupees, a 0.6% decrease compared to the previous year, significantly below the estimated 8.84 billion rupees.
- Total costs decreased by 5% year-over-year, amounting to 5.7 billion rupees.
- Other income rose by 23% to 437.2 million rupees for the quarter.
- Shares of GSK Pharma India fell by 2% to 3,099 rupees with 39,968 shares traded.
- Analyst ratings for the company’s stock include 2 buys, 1 hold, and 1 sell.
A look at GlaxoSmithKline PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
GlaxoSmithKline PLC, a research-based pharmaceutical company, is positioned with moderate scores across key factors according to Smartkarma Smart Scores. With a Value score of 2, the company may not be considered undervalued but still holds investment potential. Its Dividend score of 4 indicates a strong dividend payment history, making it an attractive option for income-seeking investors. In terms of Growth and Resilience, GlaxoSmithKline PLC is rated at 3, reflecting a steady but not exceptional performance in these areas. The Momentum score of 3 suggests a stable market position without significant upward or downward trends.
Despite facing some challenges, GlaxoSmithKline PLC remains a diversified player in the pharmaceutical industry, offering a range of products for various health needs including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. Investors considering the long-term outlook for GlaxoSmithKline PLC would find a balance of dividend strength and growth potential, although further analysis beyond the Smartkarma Smart Scores may be needed to make informed investment decisions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
